Literature DB >> 28631696

[Ankylosing spondylitis and non-radiographic axial spondyloarthritis: Two stages of disease?]

D G Rumyantseva1, T V Dubinina1, A B Demina1, O A Rumyantseva1, E M Agafonova1, A V Smirnov1, Sh F Erdes1.   

Abstract

AIM: To compare the clinical manifestations of ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nrAxSpA). SUBJECTS AND METHODS: A Moscow early spondyloarthritis cohort has now included 132 patients with axial spondyloarthritis, of whom 69 patients who have been followed up at least 12 months are to be involved in a preliminary analysis. The mean age at the time of inclusion in the study was 28.1±5.5 years; the mean disease duration was 24.7±15.8 months; 63 (91.3%) patients were HLA-B27 positive; 41 and 28 included patients were diagnosed with AS and nrAxSpA, respectively.
RESULTS: Men were significantly more in the AS group than in the nrAxSpA group (58.5 and 32.1%, respectively; p=0.05). The patients of the two groups did not differ in main clinical parameters (the presence of arthritis and enthesitis), disease activity (BASDAI, ASDAS-CRP) and functional status (BASFI). All indicators of inflammatory activity decreased nearly 2-fold in both groups after 12 months of follow up. In 7 (25%) patients with nrAxSpA, radiologically detectable sacroiliitis (SI) developed over 12 months and the diagnosis of AS was verified. Among them, 2 (28.5%) patients had initially active SI detected by magnetic resonance imaging (MRI); 4 (57.1%) had chronic SI, and 1 (14.4%) had no pathological MRI changes.
CONCLUSION: Due to the fact that the clinical manifestations of AS and nrAxSpA are comparable, it can be assumed that the latter is an early stage of AS.

Entities:  

Keywords:  Moscow cohort; ankylosing spondylitis; axial spondyloarthritis; non-radiographic axial spondyloarthritis; sacroiliitis; spondyloarthritis

Mesh:

Year:  2017        PMID: 28631696     DOI: 10.17116/terarkh201789533-37

Source DB:  PubMed          Journal:  Ter Arkh        ISSN: 0040-3660            Impact factor:   0.467


  2 in total

1.  Research hotspots and trends analysis of ankylosing spondylitis: a bibliometric and scientometric analysis from 2009 to 2018.

Authors:  Miaomiao Liang; Yan Meng; Siming Zhou; Zhengbo Tao; Lin Tao
Journal:  Ann Transl Med       Date:  2020-11

Review 2.  Spotlight on certolizumab pegol in the treatment of axial spondyloarthritis: efficacy, safety and place in therapy.

Authors:  Josefina Marin; María Laura Acosta Felquer; Enrique R Soriano
Journal:  Open Access Rheumatol       Date:  2018-05-07
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.